The present article, adapted from the Journal Circulation, describes the longest research which states that statins reduce mortality among men with high LDL-C levels without pre-existing heart disease by 28 %. Patients with elevated cholesterol are at a higher risk of developing the atherosclerotic cardiovascular disease because of long-term exposure to markedly elevated LDL-C levels. Therefore, initiation of statin therapy is recommended for these individuals.
However, there is a lack of randomised trial evidence supporting these recommendations in primary prevention. Researchers, in the longest trial to date, spanning 20 years, found that a daily dose of 40 mg pravastatin reduced deaths from heart disease in participants by more than a quarter. In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), Pravastatin is indicated to reduce the risk of…
